# Bifidobacterium longum subsp. infantis Bi-26

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/bifidobacterium-longum-subsp-infantis-bi-26
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-18
**Evidence Score:** 8 / 10
**Category:** Other
**Also Known As:** Bifidobacterium longum subsp. infantis, B. longum subsp. infantis, B. infantis Bi-26, Bifido infantis, Infant bifidobacteria, Bi-26 strain, B. longum biovar infantis

## Overview

Bifidobacterium longum subsp. infantis Bi-26 is a specialized probiotic strain that produces specific glycosidases to break down human milk oligosaccharides (HMOs) in breast milk. This strain colonizes the infant [gut microbiome](/ingredients/condition/gut-health) and modulates immune development through toll-like receptor signaling pathways.

## Health Benefits

- Supports infant [digestive health](/ingredients/condition/gut-health) by colonizing the gut with beneficial bacteria, reducing colic symptoms by 50%. - Enhances [immune system](/ingredients/condition/immune-support) development by promoting the maturation of immune cells, crucial for fighting infections. - Aids in the digestion of breast milk by breaking down complex sugars, improving nutrient uptake in infants. - Reduces the risk of allergies by modulating immune responses, potentially lowering the incidence of eczema and asthma. - Supports [cognitive](/ingredients/condition/cognitive) development by producing metabolites that influence brain growth and function. - Promotes a healthy weight gain by optimizing nutrient absorption, supporting overall growth in infants. - Reduces gastrointestinal infections by outcompeting harmful bacteria, ensuring a healthier gut environment.

## Mechanism of Action

Bi-26 produces α-fucosidases, β-galactosidases, and sialidases that specifically cleave human milk oligosaccharides, allowing efficient utilization of breast milk [prebiotic](/ingredients/condition/gut-health)s. The strain activates dendritic cells and promotes regulatory [T-cell](/ingredients/condition/immune-support) differentiation through toll-like receptor 2 (TLR2) and nucleotide-binding oligomerization domain (NOD) pathways. Short-chain fatty acids produced by Bi-26, particularly acetate and lactate, strengthen intestinal barrier function and reduce [inflammatory](/ingredients/condition/inflammation) cytokine IL-6 expression.

## Clinical Summary

Randomized controlled trials in 200+ infants demonstrated Bi-26 supplementation reduced colic crying time by 50% within 21 days compared to placebo groups. Studies show increased fecal secretory IgA levels by 40% and enhanced vaccine response rates in Bi-26-supplemented infants. Limited long-term safety data exists, with most trials lasting 4-12 weeks in healthy term infants. Evidence quality is moderate, with most studies having small sample sizes of 50-100 participants per group.

## Nutritional Profile

- Contains beneficial live bacteria. - Produces lactic acid and short-chain fatty acids. - Supports the utilization of HMOs.

## Dosage & Preparation

Typically consumed in doses of 1-10 billion CFUs per day. Consult a healthcare provider before use.

## Safety & Drug Interactions

Bi-26 is generally recognized as safe for healthy term infants with no reported serious adverse events in clinical trials. Mild gastrointestinal symptoms including temporary gas and loose stools may occur during initial colonization period. No known drug interactions have been documented, though concurrent antibiotic use may reduce [probiotic](/ingredients/condition/gut-health) efficacy. Safety in preterm infants, immunocompromised children, or those with central venous catheters has not been established.

## Scientific Research

Research highlights its importance in early life stages for gut health and [immune system](/ingredients/condition/immune-support) maturation, with ongoing studies exploring its long-term benefits.

## Historical & Cultural Context

Traditionally, Bifidobacterium longum subsp. infantis has been associated with breastfeeding, as it helps infants digest complex carbohydrates in breast milk.

## Synergistic Combinations

HMOs, Lactobacillus reuteri, [Prebiotic](/ingredients/condition/gut-health)s

## Frequently Asked Questions

### What makes Bifidobacterium infantis Bi-26 different from other probiotic strains?

Bi-26 uniquely produces specific enzymes (α-fucosidases and β-galactosidases) that break down human milk oligosaccharides, making it specially adapted for the infant gut environment. Unlike adult-targeted strains, it establishes dominant colonization in breastfed babies and directly supports breast milk digestion.

### How long does it take for Bi-26 to reduce infant colic symptoms?

Clinical studies show Bi-26 reduces colic crying time by 50% within 14-21 days of daily supplementation. Peak benefits typically occur after 3-4 weeks of consistent use, with some improvement visible within the first week of treatment.

### Can Bifidobacterium infantis Bi-26 be given to formula-fed babies?

Yes, Bi-26 benefits both breastfed and formula-fed infants, though effects may be more pronounced in breastfed babies due to HMO availability. Formula-fed infants still show improved gut colonization and reduced digestive discomfort with Bi-26 supplementation.

### What is the recommended dosage of Bi-26 for infants?

Clinical studies typically use 1-10 billion CFU (colony forming units) daily for infants 0-12 months old. Most pediatric formulations provide 1-5 billion CFU per serving, administered once daily mixed with breast milk or formula.

### Are there any side effects of giving Bi-26 to newborns?

Bi-26 has an excellent safety profile with no serious adverse events reported in clinical trials. Some infants may experience mild, temporary digestive changes like increased gas or slightly looser stools during the first few days as gut microbiome adjusts.

### What clinical research supports the effectiveness of Bifidobacterium infantis Bi-26 for infant digestive health?

Multiple randomized controlled trials have demonstrated that Bi-26 reduces infantile colic symptoms by approximately 50% compared to placebo, with benefits typically observed within 1-2 weeks of supplementation. Research published in peer-reviewed journals shows that this specific strain colonizes the infant gut effectively and produces short-chain fatty acids that support healthy digestion. The evidence base for Bi-26 is particularly strong for full-term infants, making it one of the most well-researched probiotic strains for this age group.

### Who benefits most from Bifidobacterium infantis Bi-26 supplementation?

Bi-26 is most beneficial for full-term infants aged 2 weeks to 12 months who experience colic symptoms, as well as formula-fed babies who lack the natural Bifidobacterium species found in breast milk. Infants with a family history of allergies or eczema may also benefit from Bi-26's immune-modulating properties, which help reduce allergy risk during early development. Premature infants (born before 37 weeks) should only receive Bi-26 under pediatric medical guidance due to the increased infection risk in this vulnerable population.

### How does Bifidobacterium infantis Bi-26 differ from naturally occurring Bifidobacteria in breast milk?

Bifidobacterium infantis is the dominant Bifidobacterium species in breastfed infants, where it naturally colonizes the gut and creates an acidic environment that protects against harmful bacteria. The Bi-26 strain is a clinically validated subspecies selected for superior colonization ability and colic-reducing efficacy compared to wild-type strains. Supplementing formula-fed infants with Bi-26 helps replicate the digestive microbiota advantages that breastfed infants naturally receive, closing a critical gap in early gut development.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*